New hope for myelofibrosis patients: drug combo trial targets those failed by standard therapy
Disease control
Recruiting now
This early-stage trial tests a new drug called roginolisib combined with the standard drug ruxolitinib in 26 adults with myelofibrosis whose disease did not respond to approved JAK inhibitors. The main goal is to check the safety and tolerability of the combination. Researchers w…
Phase: PHASE1, PHASE2 • Sponsor: iOnctura • Aim: Disease control
Last updated May 17, 2026 03:25 UTC